143 related articles for article (PubMed ID: 9649157)
1. Moderate amplifications of the c-myc gene correlate with molecular and clinicopathological parameters in colorectal cancer.
Masramon L; Arribas R; Tórtola S; Perucho M; Peinado MA
Br J Cancer; 1998 Jun; 77(12):2349-56. PubMed ID: 9649157
[TBL] [Abstract][Full Text] [Related]
2. Investigation of c-myc oncogene amplification in colorectal cancer.
Kozma L; Kiss I; Szakáll S; Ember I
Cancer Lett; 1994 Jun; 81(2):165-9. PubMed ID: 8012933
[TBL] [Abstract][Full Text] [Related]
3. Overexpression and amplification of c-myc during progression of human colorectal cancer.
Rochlitz CF; Herrmann R; de Kant E
Oncology; 1996; 53(6):448-54. PubMed ID: 8960139
[TBL] [Abstract][Full Text] [Related]
4. Fish detected p53 deletion and N-MYC amplification in colorectal cancer.
Ozakyol A; Ozdemir M; Artan S
Hepatogastroenterology; 2006; 53(68):192-5. PubMed ID: 16608022
[TBL] [Abstract][Full Text] [Related]
5. Amplification of c-myc in hepatocellular carcinoma: correlation with clinicopathologic features, proliferative activity and p53 overexpression.
Kawate S; Fukusato T; Ohwada S; Watanuki A; Morishita Y
Oncology; 1999; 57(2):157-63. PubMed ID: 10461064
[TBL] [Abstract][Full Text] [Related]
6. Assessment of genomic damage in colorectal cancer by DNA fingerprinting: prognostic applications.
Arribas R; Capellà G; Tórtola S; Masramon L; Grizzle WE; Perucho M; Peinado MA
J Clin Oncol; 1997 Oct; 15(10):3230-40. PubMed ID: 9336360
[TBL] [Abstract][Full Text] [Related]
7. Low-level c-myc amplification in human colonic carcinoma cell lines and tumors: a frequent, p53-independent mutation associated with improved outcome in a randomized multi-institutional trial.
Augenlicht LH; Wadler S; Corner G; Richards C; Ryan L; Multani AS; Pathak S; Benson A; Haller D; Heerdt BG
Cancer Res; 1997 May; 57(9):1769-75. PubMed ID: 9135021
[TBL] [Abstract][Full Text] [Related]
8. HER2, TOP2A, CCND1, EGFR and C-MYC oncogene amplification in colorectal cancer.
Al-Kuraya K; Novotny H; Bavi P; Siraj AK; Uddin S; Ezzat A; Sanea NA; Al-Dayel F; Al-Mana H; Sheikh SS; Mirlacher M; Tapia C; Simon R; Sauter G; Terracciano L; Tornillo L
J Clin Pathol; 2007 Jul; 60(7):768-72. PubMed ID: 16882699
[TBL] [Abstract][Full Text] [Related]
9. Clinical and pathological associations with p53 tumour-suppressor gene mutations and expression of p21WAF1/Cip1 in colorectal carcinoma.
Slebos RJ; Baas IO; Clement M; Polak M; Mulder JW; van den Berg FM; Hamilton SR; Offerhaus GJ
Br J Cancer; 1996 Jul; 74(2):165-71. PubMed ID: 8688317
[TBL] [Abstract][Full Text] [Related]
10. Genetic tumor markers with prognostic impact in Dukes' stages B and C colorectal cancer patients.
Diep CB; Thorstensen L; Meling GI; Skovlund E; Rognum TO; Lothe RA
J Clin Oncol; 2003 Mar; 21(5):820-9. PubMed ID: 12610180
[TBL] [Abstract][Full Text] [Related]
11. Analysis of the c-myc, K-ras and p53 genes in methylcholanthrene-induced mouse sarcomas.
Watanabe H; Shimokado K; Asahara T; Dohi K; Niwa O
Jpn J Cancer Res; 1999 Jan; 90(1):40-7. PubMed ID: 10076563
[TBL] [Abstract][Full Text] [Related]
12. Replication error phenotype, clinicopathological variables, and patient outcome in Dukes' B stage II (T3,N0,M0) colorectal cancer.
Curran B; Lenehan K; Mulcahy H; Tighe O; Bennett MA; Kay EW; O'Donoghue DP; Leader M; Croke DT
Gut; 2000 Feb; 46(2):200-4. PubMed ID: 10644313
[TBL] [Abstract][Full Text] [Related]
13. Chromosomal instability and p53 inactivation are required for genesis of glioblastoma but not for colorectal cancer in patients with germline mismatch repair gene mutation.
Leung SY; Yuen ST; Chan TL; Chan AS; Ho JW; Kwan K; Fan YW; Hung KN; Chung LP; Wyllie AH
Oncogene; 2000 Aug; 19(35):4079-83. PubMed ID: 10962567
[TBL] [Abstract][Full Text] [Related]
14. Characterization of p53 gene mutations in colorectal carcinomas from an Asian population.
Shi CY; Phang TW; Ngoi SS; Wee A; Li B; Lin Y; Lee HP; Ong CN
Anticancer Res; 1994; 14(6B):2811-6. PubMed ID: 7872723
[TBL] [Abstract][Full Text] [Related]
15. Is the presence of distant metastasis associated with c-myc amplification in gastric cancer?
Hajdú J; Kozma L; Kiss I; Szentkereszty Z; Szakáll S; Ember I
Acta Chir Hung; 1997; 36(1-4):119-21. PubMed ID: 9408311
[TBL] [Abstract][Full Text] [Related]
16. Heterogeneous expression and association of beta-catenin, p16 and c-myc in multistage colorectal tumorigenesis and progression detected by tissue microarray.
Xie D; Sham JS; Zeng WF; Lin HL; Che LH; Wu HX; Wen JM; Fang Y; Hu L; Guan XY
Int J Cancer; 2003 Dec; 107(6):896-902. PubMed ID: 14601048
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of myc and chromosome 8 copy number in colorectal cancer using interphase cytogenetics.
Obara K; Yokoyama M; Asano G; Tanaka S
Int J Oncol; 2001 Feb; 18(2):233-9. PubMed ID: 11172587
[TBL] [Abstract][Full Text] [Related]
18. Comparative analysis of the EGFR, HER2, c-MYC, and MET variations in colorectal cancer determined by three different measures: gene copy number gain, amplification status and the 2013 ASCO/CAP guideline criterion for HER2 testing of breast cancer.
Kwak Y; Yun S; Nam SK; Seo AN; Lee KS; Shin E; Oh HK; Kim DW; Kang SB; Kim WH; Lee HS
J Transl Med; 2017 Aug; 15(1):167. PubMed ID: 28764718
[TBL] [Abstract][Full Text] [Related]
19. APC, K-ras, and p53 gene mutations in colorectal cancer patients: correlation to clinicopathologic features and postoperative surveillance.
Hsieh JS; Lin SR; Chang MY; Chen FM; Lu CY; Huang TJ; Huang YS; Huang CJ; Wang JY
Am Surg; 2005 Apr; 71(4):336-43. PubMed ID: 15943410
[TBL] [Abstract][Full Text] [Related]
20. Loss of heterozygosity of TP53 is not correlated with clinicopathological variables in sporadic colorectal carcinomas.
González-Aguilera JJ; Herrero MP; Maillo C; Moreno-Azcoita M; Fernández-Peralta AM
Anticancer Res; 1999; 19(2A):1325-9. PubMed ID: 10368694
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
